Mesenchymal stem cell–based tissue regeneration is governed by recipient T lymphocytes via IFN-γ and TNF-α

Article metrics

Abstract

Stem cell–based regenerative medicine is a promising approach in tissue reconstruction. Here we show that proinflammatory T cells inhibit the ability of exogenously added bone marrow mesenchymal stem cells (BMMSCs) to mediate bone repair. This inhibition is due to interferon γ (IFN-γ)–induced downregulation of the runt-related transcription factor 2 (Runx-2) pathway and enhancement of tumor necrosis factor α (TNF-α) signaling in the stem cells. We also found that, through inhibition of nuclear factor κB (NF-κB), TNF-α converts the signaling of the IFN-γ–activated, nonapoptotic form of TNF receptor superfamily member 6 (Fas) in BMMSCs to a caspase 3– and caspase 8–associated proapoptotic cascade, resulting in the apoptosis of these cells. Conversely, reduction of IFN-γ and TNF-α concentrations by systemic infusion of Foxp3+ regulatory T cells, or by local administration of aspirin, markedly improved BMMSC-based bone regeneration and calvarial defect repair in C57BL/6 mice. These data collectively show a previously unrecognized role of recipient T cells in BMMSC-based tissue engineering.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: T cells regulated BMMSC-mediated bone formation.
Figure 2: Treg cells improved BMMSC-mediated bone formation in wild-type C57BL/6 mice.
Figure 3: IFN-γ inhibited the osteogenic differentiation of BMMSCs.
Figure 4: IFN-γ synergistically enhanced BMMSC apoptosis induced by TNF-α through the Fas apoptotic pathway.
Figure 5: IFN-γ synergistically enhanced TNF-α–induced BMMSC apoptosis through inhibition of the TNFR2–NF-κB pathway and Fas internalization.
Figure 6: Treg cell infusion and aspirin treatment improved BMMSC-mediated bone formation.

References

  1. 1

    Bianco, P., Riminucci, M., Gronthos, S. & Robey, P.G. Bone marrow stromal stem cells: nature, biology, and potential applications. Stem Cells 19, 180–192 (2001).

  2. 2

    Friedenstein, A.J., Chailakhyan, R.K., Latsinik, N.V., Panasyuk, A.F. & Keiliss-Borok, I.V. Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo. Transplantation 17, 331–340 (1974).

  3. 3

    Owen, M. & Friedenstein, A.J. Stromal stem cells: marrow-derived osteogenic precursors. Ciba Found. Symp. 136, 42–60 (1988).

  4. 4

    Pittenger, M.F. et al. Multilineage potential of adult human mesenchymal stem cells. Science 284, 143–147 (1999).

  5. 5

    Prockop, D.J. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 276, 71–74 (1997).

  6. 6

    Caplan, A.I. Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. J. Cell. Physiol. 213, 341–347 (2007).

  7. 7

    García-Gómez, I. et al. Mesenchymal stem cells: biological properties and clinical applications. Expert Opin. Biol. Ther. 10, 1453–1468 (2010).

  8. 8

    Tasso, R., Fais, F., Reverberi, D., Tortelli, F. & Cancedda, R. The recruitment of two consecutive and different waves of host stem/progenitor cells during the development of tissue-engineered bone in a murine model. Biomaterials 31, 2121–2129 (2010).

  9. 9

    Bueno, E.M. & Glowacki, J. Cell-free and cell-based approaches for bone regeneration. Nat. Rev. Rheumatol. 5, 685–697 (2009).

  10. 10

    Zhao, S. et al. Immunomodulatory properties of mesenchymal stromal cells and their therapeutic consequences for immune-mediated disorders. Stem Cells Dev. 19, 607–614 (2010).

  11. 11

    Tolar, J., Le Blanc, K., Keating, A. & Blazar, B.R. Concise review: hitting the right spot with mesenchymal stromal cells. Stem Cells 28, 1446–1455 (2010).

  12. 12

    English, K., French, A. & Wood, K.J. Mesenchymal stromal cells: facilitators of successful transplantation? Cell Stem Cell 7, 431–442 (2010).

  13. 13

    Sun, L. et al. Mesenchymal stem cell transplantation reverses multi-organ dysfunction in systemic lupus erythematosus mice and humans. Stem Cells 27, 1421–1432 (2009).

  14. 14

    Spaggiari, G.M., Capobianco, A., Becchetti, S., Mingari, M.C. & Moretta, L. Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2–induced NK-cell proliferation. Blood 107, 1484–1490 (2006).

  15. 15

    Yamaza, T. et al. Pharmacologic stem cell based intervention as a new approach to osteoporosis treatment in rodents. PLoS ONE 3, e2615 (2008).

  16. 16

    Lourenço, E.V. & La Cava, A. Natural regulatory T cells in autoimmunity. Autoimmunity 44, 33–42 (2011).

  17. 17

    Zhou, X. et al. Therapeutic potential of TGF-β–induced CD4+ Foxp3+ regulatory T cells in autoimmune diseases. Autoimmunity 44, 43–50 (2011).

  18. 18

    Shevach, E.M. CD4+CD25+ suppressor T cells: more question than answers. Nat. Rev. Immunol. 2, 389–400 (2002).

  19. 19

    van Mierlo, G.J. et al. Cutting edge: TNFR-shedding by CD4+CD25+ regulatory T cells inhibits the induction of inflammatory mediators. J. Immunol. 180, 2747–2751 (2008).

  20. 20

    Ura, K. et al. Interleukin (IL)-4 and IL-13 inhibit the differentiation of murine osteoblastic MC3T3-E1 cells. Endocr. J. 47, 293–302 (2000).

  21. 21

    Krebsbach, P.H. et al. Bone formation in vivo: comparison of osteogenesis by transplanted mouse and human marrow stromal fibroblasts. Transplantation 63, 1059–1069 (1997).

  22. 22

    Batouli, S. et al. Comparison of stem cell–mediated osteogenesis and dentinogenesis. J. Dent. Res. 82, 976–981 (2003).

  23. 23

    Kwon, M.S. et al. Effect of aspirin and acetaminophen on proinflammatory cytokine-induced pain behavior in mice. Pharmacology 74, 152–156 (2005).

  24. 24

    Kwan, M.D., Slater, B.J., Wan, D.C. & Longaker, M.T. Cell-based therapies for skeletal regenerative medicine. Hum. Mol. Genet. 17, R93–R98 (2008).

  25. 25

    Panetta, N.J., Gupta, D.M., Quarto, N. & Longaker, M.T. Mesenchymal cells for skeletal tissue engineering. Panminerva Med. 51, 25–41 (2009).

  26. 26

    Fredericks, D.C. et al. Cellular interactions and bone healing responses to a novel porous tricalcium phosphate bone graft material. Orthopedics 27, s167–s173 (2004).

  27. 27

    Seong, J.M. et al. Stem cells in bone tissue engineering. Biomed. Mater. 5, 062001 (2010).

  28. 28

    Undale, A.H., Westendorf, J.J., Yaszemski, M.J. & Khosla, S. Mesenchymal stem cells for bone repair and metabolic bone diseases. Mayo Clin. Proc. 84, 893–902 (2009).

  29. 29

    Kogianni, G. et al. Fas/CD95 is associated with glucocorticoid-induced osteocyte apoptosis. Life Sci. 75, 2879–2895 (2004).

  30. 30

    Hess, S. & Engelmann, H. A novel function of CD40: induction of cell death in transformed cells. J. Exp. Med. 183, 159–167 (1996).

  31. 31

    Li, J.Y. et al. Ovariectomy disregulates osteoblast and osteoclast formation through the T-cell receptor CD40 ligand. Proc. Natl. Acad. Sci. USA 108, 768–773 (2011).

  32. 32

    Ahuja, S.S. et al. CD40 ligand blocks apoptosis induced by tumor necrosis factor α, glucocorticoids, and etoposide in osteoblasts and the osteocyte-like cell line murine long bone osteocyte-Y4. Endocrinology 144, 1761–1769 (2003).

  33. 33

    Schrum, L.W. et al. Functional CD40 expression induced following bacterial infection of mouse and human osteoblasts. Infect. Immun. 71, 1209–1216 (2003).

  34. 34

    Li, Z. et al. IFN-γ enhances HOS and U2OS cell lines susceptibility to γδ T cell–mediated killing through the Fas/Fas ligand pathway. Int. Immunopharmacol. 11, 496–503 (2011).

  35. 35

    Shen, R. et al. Smad6 intereacts with Runx2 and mediates Smad ubiquitin regulatory factor 1–induced Runx2 degradation. J. Biol. Chem. 281, 3569–3576 (2006).

  36. 36

    Itoh, F. et al. Promoting bone morphogenetic protein signaling through negative regulation of inhibitory Smads. EMBO J. 20, 4132–4142 (2001).

  37. 37

    Qin, J.Z. et al. Role of NF-κB in the apoptotic-resistant phenotype of keratinocytes. J. Biol. Chem. 274, 37957–37964 (1999).

  38. 38

    Moon, D.O., Kim, M.O., Kang, S.H., Choi, Y.H. & Kim, G.Y. Sulforaphane suppresses TNF-α–mediated activation of NF-kappaB and induces apoptosis through activation of reactive oxygen species-dependent caspase-3. Cancer Lett. 274, 132–142 (2009).

  39. 39

    Buckland, M. et al. Aspirin-treated human DCs up-regulate ILT-3 and induce hyporesponsiveness and regulatory activity in responder T cells. Am. J. Transplant. 6, 2046–2059 (2006).

  40. 40

    Shi, S. et al. Bone formation by human postnatal bone marrow stromal stem cells is enhanced by telomerase expression. Nat. Biotechnol. 20, 587–591 (2002).

Download references

Acknowledgements

We thank X. Duan and T. Zhou of the Fourth Military Medical University for generating microCT images. This work was supported by grants from the US National Institute of Dental and Craniofacial Research, US National Institutes of Health, Department of Health and Human Services (R01DE017449, R01DE019932 and R01DE019413 to S.S.), a grant from California Institute for Regenerative Medicine (RN1-00572 to S.S.) and the Intramural Program of the US National Institute of Dental and Craniofacial Research, US National Institutes of Health, Department of Health and Human Services.

Author information

Y.L. and L.W. performed the majority of the experiments, analyzed data and prepared the manuscript. T.K. maintained mice and helped with the in vivo bone formation assay. K.A. and C.C. helped with the cell apoptosis assay. X.X. helped with the flow cytometric analysis. R.Y. helped with in vivo experiments. W.C. and S.W. provided suggestions for the project. S.S. supervised the project and wrote the manuscript.

Correspondence to Songtao Shi.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary Text and Figures

Supplementary Methods and Supplementary Figures 1–11 (PDF 1977 kb)

Rights and permissions

Reprints and Permissions

About this article

Further reading